BrainCool AB (SE:BRAIN)
:BRAIN
Want to see SE:BRAIN full AI Analyst Report?
BRAIN Stock Chart & Stats
kr0.58
kr0.19(9.74%)
At close: 4:00 PM EST
kr0.58
kr0.19(9.74%)
Day’s Range― - ―
52-Week Rangekr0.41 - kr1.63
Previous CloseN/A
Volume974.66K
Average Volume (3M)201.46K
Market Cap
kr319.06M
Enterprise Valuekr159.06M
Total Cash (Recent Filing)kr51.40M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding394,878,140
10 Day Avg. Volume223,544
30 Day Avg. Volume201,464
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)kr54.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetZero reported debt and substantial equity materially reduce solvency risk and extend optionality for a medical device company. This conservatism supports funding commercialization, R&D, or working capital without immediate refinancing pressure, improving medium-term resilience.
Recurring Consumables & ServicesA business model that combines capital equipment with recurring consumables and service contracts creates predictable, repeatable revenue as installed base grows. Consumables drive customer lock-in and margin stability, aiding long-term revenue visibility once adoption scales.
Clinical Acute-care Product FitProducts addressing acute and critical care needs occupy a structurally stable hospital spend category. When clinical adoption and guideline alignment occur, device usage becomes sticky, supporting durable installed-base growth and long-term consumable demand across health systems.
Bears Say
Persistently Negative Cash FlowConsistent, large negative operating and free cash flow indicate ongoing cash burn that will require external financing or meaningful operational change. This undermines runway, limits investment capacity, and risks equity dilution or constrained execution over the next several quarters.
Deep Unprofitability And Negative Unit EconomicsNegative gross margins and chronic operating losses suggest current unit economics are unsustainable. Without margin improvement via pricing, mix shift, or cost reduction, scaling revenue may worsen losses and delay a credible path to breakeven over a multi-quarter horizon.
Softening Revenue MomentumRevenue contraction after prior scale-up signals weakening adoption or market headwinds. Falling top-line undermines leverage of fixed costs and slows growth of the consumables base, making operational turnarounds and positive cash flow harder to achieve within 2–6 months.
BrainCool AB News
BRAIN FAQ
What was BrainCool AB’s price range in the past 12 months?
BrainCool AB lowest stock price was kr0.41 and its highest was kr1.63 in the past 12 months.
What is BrainCool AB’s market cap?
BrainCool AB’s market cap is kr319.06M.
When is BrainCool AB’s upcoming earnings report date?
BrainCool AB’s upcoming earnings report date is Aug 12, 2026 which is in 81 days.
How were BrainCool AB’s earnings last quarter?
BrainCool AB released its earnings results on May 06, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.
Is BrainCool AB overvalued?
According to Wall Street analysts BrainCool AB’s price is currently Overvalued.
Does BrainCool AB pay dividends?
BrainCool AB does not currently pay dividends.
What is BrainCool AB’s EPS estimate?
BrainCool AB’s EPS estimate is 0.
How many shares outstanding does BrainCool AB have?
BrainCool AB has 394,878,140 shares outstanding.
What happened to BrainCool AB’s price movement after its last earnings report?
BrainCool AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went up 4.337%.
Which hedge fund is a major shareholder of BrainCool AB?
Currently, no hedge funds are holding shares in SE:BRAIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrainCool AB
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device. The company was incorporated in 2010 and is based in Lund, Sweden.
Technical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Acarix AB
―
Sedana Medical AB
―
Mentice AB
―